← All trials
NCT04243863
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2020
- Primary completion
- Jun 24, 2020
- Completion date
- Jun 24, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VenatoRx Pharmaceuticals, Inc.Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.